---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-389844"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2026-09-14T11:29:42+00:00"
generated_at: "2026-09-14T11:35:19.597932+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Zipalertinib+chemo meets primary endpoint in Phase 3 REZILIENT3: PFS 14.5 vs 8.5 mo, HR 0.50

## Summary
- Median PFS 14.5 vs 8.5 months (HR 0.50; 95% CI 0.34-0.73; P=0.00015) in first-line EGFR ex20ins NSCLC.
- ORR 65.0% vs 40.3% (P<0.0001); median duration of response 14.2 vs 9.9 months.
- Interim OS HR 0.72 (95% CI 0.42-1.23) at 30% maturity; follow-up ongoing.
- Safety: Grade ≥3 AEs 87.1% vs 54.4%, mostly manageable hematologic; no new signals.

## SEC filing metadata
- accession: 0001193125-26-389844
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2026-09-14T11:29:42+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312526389844/0001193125-26-389844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312526389844/cgem-20260913.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-389844
- JSON: https://secwatch.observer/filing/0001193125-26-389844.json
- Plain text: https://secwatch.observer/filing/0001193125-26-389844.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.